EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Brain‐Penetrant Nurr1 Agonist Tool

Jan Vietor, Tanja Stiller, Christian Gege, Wael Saeb, Úrsula López-García, Hella Kohlhof, Daniel Vitt, Daniel Merk iD

ChemMedChem · 15.06.2026 · 21 (11)

DOI: 10.1002/cmdc.70296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 14.06.2026. Verfasst von Jan Vietor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 4, Group A, Member 2, Brain, Thiophenes. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, ERC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ligand‐sensing transcription factor nuclear receptor‐related 1 (Nurr1), is thought to mediate neuroprotective activity and is implicated in various neurodegenerative diseases. Nurr1 ligands have been developed as tools to capture the receptor's potential in vitro and in vivo, but a dedicated brain‐targeting agonist has been lacking. Here, we employed the scaffold of the dihydroorotate dehydrogenase (DHODH) inhibitor and strong Nurr1 activator vidofludimus to develop a descendant with a high brain‐to‐blood ratio. Scaffold‐hopping from cyclopentene to thiophene, enhanced fluorination, and replacement of the carboxylic acid by an amide provided a highly potent, selective, and brain‐penetrant Nurr1 agonist to study the effects of Nurr1 activation in the central nervous system (CNS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 4, Group A, Member 2BrainThiophenesHumansAnimalsStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugCyclopentanes

Stichwörter der Autor:innen

NR4Ablood‐brain‐barriernuclear receptor‐related 1transcription factor

Substanzen

Nuclear Receptor Subfamily 4, Group A, Member 2ThiophenesCyclopentanesNR4A2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Immunic AG, Gräfelfing, Germany.
  • RebisLab R&D GmbH, Planegg-Martinsried, Germany.

ORCID-Profile: Daniel Merk

Förderung

  • European Research Council
  • ERC

Zitieren

APA

Vietor, J., Stiller, T., Gege, C., Saeb, W., López-García, Ú., Kohlhof, H., Vitt, D., & Merk, D. (2026). Development of a Brain‐Penetrant Nurr1 Agonist Tool. ChemMedChem, 21(11). https://doi.org/10.1002/cmdc.70296

Vancouver

Vietor J, Stiller T, Gege C, Saeb W, López-García Ú, Kohlhof H, et al. Development of a Brain‐Penetrant Nurr1 Agonist Tool. ChemMedChem. 2026;21(11). doi:10.1002/cmdc.70296

BibTeX
@article{Vietor2026,
  author = {Vietor, Jan and Stiller, Tanja and Gege, Christian and Saeb, Wael and López-García, Úrsula and Kohlhof, Hella and Vitt, Daniel and Merk, Daniel},
  title = {Development of a Brain‐Penetrant Nurr1 Agonist Tool},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {11},
  doi = {10.1002/cmdc.70296}
}
Kostenlos starten →